Recent Quotes (30 days)

You have no recent quotes
chg | %

BTG plc  

(Public, LON:BTG)   Watch this stock  
Find more results forLON:BGC
702.50
+0.50 (0.07%)
Real-time:   3:07pm BST
LON real-time data - Disclaimer
Currency in GBX unless noted
Range 689.00 - 706.50
52 week 528.36 - 739.50
Open 701.00
Vol / Avg. 247,371.00/1.01M
Mkt cap 2,709.83M*
P/E 81.56
Div/yield     -
EPS 0.09*
Shares 385.74M
Beta     -
Inst. own     -
*GBP
Jul 13, 2017
BTG PLC Annual Shareholders Meeting - 10:30am BST - Add to calendar
May 16, 2017
Full Year 2017 BTG PLC Earnings Call - Webcast
May 16, 2017
Full Year 2017 BTG PLC Earnings Release
May 4, 2017
BTG PLC at Deutsche Bank Health Care Conference
Apr 6, 2017
BTG PLC Close Period Update
  

Key stats and ratios

Q1 (Mar '17) 2017
Net profit margin 7.26% 5.89%
Operating margin 9.26% 9.68%
EBITD margin - 19.70%
Return on average assets 3.18% 2.73%
Return on average equity 4.33% 3.68%
Employees 1,355 -
CDP Score - C

Address

5 Fleet Place
LONDON, EC4M 7RD
United Kingdom - Map
+44-20-75750000 (Phone)
+44-20-75750010 (Fax)

Website links

External links

Analyst Estimates - BusinessWeek
Options - MarketWatch
Director Dealings - Yahoo Finance

Description

BTG plc is engaged in the business of healthcare, focusing on Interventional Medicine therapies for liver cancer, emphysema and vascular disorders, specialty pharmaceuticals for acute care uses, and a licensing business. The Company operates through three segments: Interventional Medicine, Specialty Pharmaceuticals and Licensing. The Interventional Medicine segment includes oncology, vascular and pulmonology. The segment's products include Beads, TheraSphere, EkoSonic, Varithena and PneumRx Coils for use in the treatment of liver tumors, blood clots, varicose veins and advanced emphysema. The Specialty Pharmaceuticals segment includes CroFab, DigiFab, Voraxaze and Vistogard products for use in the treatment of crotalid envenomation, digoxin toxicity, high-dose methotrexate toxicity and 5-fluorouracil toxicity. The Licensing segment includes Zytiga, Two-Part Hip Cup and Lemtrada products for use in the treatment of advanced prostate cancer, hip replacement and multiple sclerosis.

Officers and directors

Dame Pamela Louise Makin Ph.D. Chief Executive Officer, Executive Director
Rolf B. Soderstrom Chief Financial Officer, Executive Director
Paul Mussenden Company Secretary
Garry Andrew Watts Non-Executive Chairman of the Board
Age: 60
Susan Elizabeth Foden Ph.D. Non-Executive Director
Age: 63
Graham Hetherington Non-Executive Director
Age: 56
Giles Francis Bertram Kerr Senior Independent Non-Executive Director
Age: 56
Ian F. R. Much Independent Non-Executive Director